Incannex Healthcare Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder

Reuters08-26

<a href="https://laohu8.com/S/IHLXF">Incannex Healthcare</a> Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder

Incannex Healthcare Inc. has announced positive results from its Phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for Generalised Anxiety Disorder (GAD). The trial demonstrated statistically significant and clinically meaningful improvements in anxiety, mood, disability, and quality of life measures. These findings position PSX-001 as a leading psilocybin-assisted therapy currently in development. The company plans to initiate a multi-jurisdiction Phase 2 clinical trial and is seeking strategic partnerships to enhance development and global access. The results were presented as part of the company's ongoing efforts to advance its clinical pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-080509), on August 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2562735624?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562735624","market":"fut","top_or_hot":-1,"title":"Incannex Healthcare Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. has announced positive results from its Phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for Generalised Anxiety Disorder (GAD). The trial demonstrated statistically significant and clinically meaningful improvements in anxiety, mood, disability, and quality of life measures. These findings position PSX-001 as a leading psilocybin-assisted therapy currently in development. The company plans to initiate a multi-jurisdiction Phase 2 clinical trial and is seeking strategic partnerships to enhance development and global access. The results were presented as part of the company's ongoing efforts to advance its clinical pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-080509), on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incannex Healthcare Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncannex Healthcare Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-26 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IHLXF\">Incannex Healthcare</a> Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IXHL\">Incannex Healthcare</a> Inc. has announced positive results from its Phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for Generalised Anxiety Disorder (GAD). The trial demonstrated statistically significant and clinically meaningful improvements in anxiety, mood, disability, and quality of life measures. These findings position PSX-001 as a leading psilocybin-assisted therapy currently in development. The company plans to initiate a multi-jurisdiction Phase 2 clinical trial and is seeking strategic partnerships to enhance development and global access. The results were presented as part of the company's ongoing efforts to advance its clinical pipeline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-080509), on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IXHL","symbol_name":"INCANNEX HEALTHCARE LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL2Jhnhx:1","article_id":"2562735624","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562735624","pubTimestamp":1756209712,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incannex Healthcare Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder. Incannex Healthcare Inc. has announced positive results from its Phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for Generalised Anxiety Disorder . The trial demonstrated statistically significant and clinically meaningful improvements in anxiety, mood, disability, and quality of life measures. These findings position PSX-001 as a leading psilocybin-assisted therapy currently in development. The company plans to initiate a multi-jurisdiction Phase 2 clinical trial and is seeking strategic partnerships to enhance development and global access. The results were presented as part of the company's ongoing efforts to advance its clinical pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"translate_title":"Incannex Healthcare宣布裸盖菇素辅助疗法PSX-001治疗广泛性焦虑症的2期试验结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXHL":0.9},"content_text":"Incannex Healthcare Announces Positive Phase 2 Trial Results for Psilocybin-Assisted Therapy PSX-001 in Treating Generalised Anxiety Disorder\n    \n\nIncannex Healthcare Inc. has announced positive results from its Phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for Generalised Anxiety Disorder (GAD). The trial demonstrated statistically significant and clinically meaningful improvements in anxiety, mood, disability, and quality of life measures. These findings position PSX-001 as a leading psilocybin-assisted therapy currently in development. The company plans to initiate a multi-jurisdiction Phase 2 clinical trial and is seeking strategic partnerships to enhance development and global access. The results were presented as part of the company's ongoing efforts to advance its clinical pipeline.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-080509), on August 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2562735624","isCrawlerRequest":true}